Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
Julissa Viana
Vice President of Corporate Communications & Investor Relations
Good morning, everyone. For those that don’t know me, I’m Julissa Viana, the Senior Vice President of Corporate Communications, Investor Relations and Patient Advocacy. We’re really excited to have you here today, and thank you for those that are listening via the live stream. Please note that this event is being recorded and will be available on our website afterwards.
This morning, we are very excited to discuss VS-7375, our best-in-class, highly selective oral KRAS G12D ON/OFF inhibitor, which is being evaluated in multiple clinical trials. Today, we’ll share new clinical data from our TARGET-D 101 trial, including for the first time, U.S. efficacy data and updated safety and tolerability results in KRAS G12D mutated pancreatic, colorectal and lung cancers.
This morning, we issued a very long press release detailing these results, along with a slide presentation that we’ll reference today. Both are available on our website.
The next slide. Let’s see… all right. I won’t be reading the slide, but I do need to point out that we’ll be making forward-looking statements that are based on our
